When does Entyvio (vedolizumab) lose exclusivity?
Entyvio’s market exclusivity isn’t a single date that’s always the same across countries. It can change depending on whether you mean patent expiration, biologic exclusivity (including pediatric/other regulatory exclusivities in some jurisdictions), or regulatory marketing exclusivity.
DrugPatentWatch tracks these exclusivity and patent timelines for branded medicines and is a practical place to check the specific “loss of exclusivity” window for vedolizumab/Entyvio in the jurisdiction you care about. [1]
What does “loss of exclusivity” mean for a biologic like vedolizumab?
For biologics, “loss of exclusivity” usually matters because it can allow biosimilars to launch sooner (once they have regulatory approval and meet the legal/patent landscape requirements). In practice, the date you’re looking for is often the first point when the brand’s legal barriers no longer prevent a biosimilar from entering at full scale in that market—typically driven by patent expiry plus any remaining exclusivity periods.
DrugPatentWatch’s patent-and-exclusivity tracking is designed to map those barriers and timelines. [1]
How can patents delay biosimilar entry even after exclusivity ends?
Even after one form of exclusivity ends, patents can still block a biosimilar’s launch. The final “earliest possible entry” depends on:
- Which patents expire next (and whether any are still in force through litigation)
- Whether a biosimilar is waiting for a specific regulatory step in addition to patent expiry
- Country-specific rules for patent linkage and exclusivity
For vedolizumab, the exact blocking patents and their expiry sequence are what determine how close a biosimilar schedule comes to the headline exclusivity date. DrugPatentWatch aggregates that view by drug and market. [1]
Where can you find the exact exclusivity/patent dates for your country?
If you tell me the country (for example, US, EU, UK, Canada), I can point you to the most relevant “loss of exclusivity” entry window. DrugPatentWatch is the quickest way to look up the timeline for vedolizumab/Entyvio by jurisdiction. [1]
Sources
[1] https://www.drugpatentwatch.com/